Pyxis Oncology, Inc.
PYXS- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001782223
No open-market purchases or sales by Pyxis Oncology, Inc. insiders were filed in the last 90 days; 76 institutions reported holding it in 13F filings for Q2 2026, worth $101.1M in total; no superinvestor holds it.
13F holders, Q4 2024
Institutional positions in Pyxis Oncology, Inc. as of Dec 31, 2024. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 99
- +7 vs. Q3 2024
- Shares held
- 31.6M
- +3.67M (+13.2%) vs. Q3 2024
- Total value
- $49.2M
- −$53.1M (−51.9%) vs. Q3 2024
- New holders
- 25
- 33 more added
- Sold out
- 18
- 19 more reduced
Compare with Q3 2024: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting PYXS on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 76 | $101.1M |
| Q1 2026 | 78 | $40.5M |
| Q4 2025 | 79 | $34.7M |
| Q3 2025 | 73 | $59.7M |
| Q2 2025 | 74 | $30.2M |
| Q1 2025 | 89 | $29.6M |
| Q4 2024 | 99 | $49.2M |
| Q3 2024 | 92 | $102.3M |
| Q2 2024 | 80 | $93.1M |
| Q1 2024 | 71 | $97.7M |
| Q4 2023 | 51 | $15.8M |
| Q3 2023 | 54 | $15.4M |
| Q2 2023 | 48 | $24.6M |
| Q1 2023 | 47 | $41.5M |
| Q4 2022 | 31 | $26.5M |
| Q3 2022 | 38 | $38.3M |
| Q2 2022 | 39 | $47.7M |
| Q1 2022 | 45 | $76.1M |
| Q4 2021 | 51 | $199.9M |
| Q3 2021 | 0 | $0 |
| Q2 2021 | 0 | $0 |
| Q1 2021 | 0 | $0 |
Institutions, Q4 2024
Shares, value and share of portfolio for each institution holding Pyxis Oncology, Inc.; share changes are against Q3 2024.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Blue Owl Capital Holdings LP | 0 | $0 | 0.00% | −1,126,025−100.0% | Sold out |
| StemPoint Capital LP | 0 | $0 | 0.00% | −850,210−100.0% | Sold out |
| Citadel Advisors LLC | 0 | $0 | 0.00% | −275,951−100.0% | Sold out |
| Balyasny Asset Management LLC | 0 | $0 | 0.00% | −224,957−100.0% | Sold out |
| Sherbrooke Park Advisers LLC | 0 | $0 | 0.00% | −18,890−100.0% | Sold out |
| MetLife Investment Management | 0 | $0 | 0.00% | −18,818−100.0% | Sold out |
| Manufacturers Life Insurance Company, The | 0 | $0 | 0.00% | −18,638−100.0% | Sold out |
| SG Americas Securities, LLC | 0 | $0 | 0.00% | −15,800−100.0% | Sold out |
| Fullcircle Wealth LLC | 0 | $0 | 0.00% | −13,660−100.0% | Sold out |
| HSBC Holdings PLC | 0 | $0 | 0.00% | −11,358−100.0% | Sold out |
| Blair William & Co | 0 | $0 | 0.00% | −10,000−100.0% | Sold out |
| Group One Trading, L.P. | 0 | $0 | 0.00% | −2,000−100.0% | Sold out |
| Harbour Investments, Inc. | 0 | $0 | 0.00% | −581−100.0% | Sold out |
| Lazard Asset Management LLC | 0 | $0 | 0.00% | −369−100.0% | Sold out |
| Capital Performance Advisors LLP | 0 | $0 | 0.00% | −142−100.0% | Sold out |
| Nisa Investment Advisors, LLC | 0 | $0 | 0.00% | −118−100.0% | Sold out |
| International Assets Investment Management, LLC | 0 | $0 | 0.00% | −3,854−100.0% | Sold out |